A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex

GlaxoSmithKline (GSK)

Status and phase

Completed

Phase 3

Conditions

AIDS Dementia Complex

HIV Infections

Treatments

Drug: Abacavir sulfate

Study type

Interventional

Funder types

Industry

Identifiers

NCT00002163

CNAB 3001

238B

Details and patient eligibility

About

To evaluate the benefit of adding 1592U89 to current antiretroviral therapies for AIDS dementia complex and to assess the safety and tolerance of the treatment regimens.

Full description

Patients must be on stable antiretroviral treatment for at least 6 weeks prior to study entry and will then be stratified depending on whether their regimen contains zidovudine (ZDV). Each stratum will be randomized separately to receive 1592U89 or placebo for 12 weeks. For the subsequent 40 weeks, open-label 1592U89 will be offered.

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Patients must have:

Documented HIV infection.
Evidence of HIV - associated dementia.
Been on stable antiretroviral treatment for a minimum of 6 weeks prior to study entry.

Exclusion Criteria

Co-existing Condition:

Patients with any of the following symptoms or conditions are excluded:

Debilitated as a result of their HIV disease, associated illness or therapies who the investigator determines will not be able to complete the 12 week randomized dosing period.
Memorial Sloan-Kettering (MSK) score of >= 3 for dementia.
Confounding neurological diseases which may interfere with interpretation of neurological and neurophysical assessments.
Malabsorption syndrome or other gastrointestinal dysfunction which renders them unable to take oral medication.
Chronic diseases such as diabetes, congestive heart failure, cardiomyopathy, other cardiac dysfunctions, etc., which in the investigator's opinion would compromise the safety of the patient.
Symptomatic AIDS-defining opportunistic infection not responsive to therapy.

Concurrent Medication:

Excluded:

Treatment with cytotoxic chemotherapeutic agents within the first 12 weeks of the study.
Treatment with nerve growth factor within the first 12 weeks of study.
The use of narcotic analgesics, sedatives, benzodiazepines, antidepressants, anti-psychotic agents and other psychoactive drugs which would interfere with the assessment of the neurological and neurophysical status of the patient.
Use of stavudine (d4T) during the first 12 weeks of the study.
Immunomodulating agents (except GM/G-CSF or epoietin).
Psychoactive drugs (at the investigator's discretion).

Concurrent Treatment:

Excluded:

Treatment with radiation therapy within the first 12 weeks of the study.

NOTE:

With the exception of local treatment for Kaposi's sarcoma.

Patients with any of the following prior conditions are excluded:

Previous neurological disease unrelated to HIV infection.
History of clinically apparent hepatitis within the last 6 months.
History of clinically apparent pancreatitis in the last 6 months.

Prior Medication:

Excluded:

Treatment with cytotoxic chemotherapeutic agents within 1 month of entry.
Participation in investigational antiretroviral trials within the past 3 months.
HIV vaccine within the past 3 months.
Treatment with immunomodulating agents such as systemic corticosteroids, interleukins, thalidomide, anticytokine agents, anti-oxidants or interferons within 1 month of study entry.
Nerve growth factor.

Prior Treatment:

Excluded: